register free | resend password


PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

ID: 1519166
recent pressrelease next pressrelease

(Thomson Reuters ONE) -


REGULATED INFORMATION


GHENT, Belgium, 30 August 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose securities are
admitted to trading on a regulated market (the "Transparency Law"), that it
received a notification of shareholdings from Bank of America Corporation on 25
August 2017.

Bank of America Corporation (taking into account the holdings of its subsidiary
undertakings) notified Ablynx that it has exceeded the 5% threshold as of 18
August 2017 and now holds a total of 3,159,205 shares with voting rights,
representing 5.16% of the current 61,169,732 outstanding Ablynx shares (versus
4.97% notified previously on 5 July 2017).

The notified details are presented below:

+-----------------------+----------------+-----------------------+-------------+
|Name of select | |% of voting rights held| |
|subsidiaries of | % of voting | through financial |Total of both|
|Bank of America | rights | instruments** | |
|Corporation* | | | |
+-----------------------+----------------+-----------------------+-------------+
|Merrill Lynch Pierce, | 0.001% |   | 0.001% |
|Fenner & Smith Incorp. | | | |
+-----------------------+----------------+-----------------------+-------------+
|Merrill Lynch | | | |
|Professional Clearing |   | 5.16% | 5.16% |
|Corp. | | | |
+-----------------------+----------------+-----------------------+-------------+


|TOTAL | 0.001% | 5.16% | 5.16% |
+-----------------------+----------------+-----------------------+-------------+

* Merrill Lynch Professional Clearing Corporation and Merrill Lynch Pierce,
Fenner & Smith Incorporated are controlled by Bank of America Corporation. Bank
of America Corporation is not a controlled entity.
** Type of financial instrument: "Right of Use" that represents a right of
rehypothecation (not yet exercised) that Merrill Lynch Professional Clearing
Corporation has over stock held on behalf of Prime Brokerage clients. The
underlying shares are common stock. The company holds the shares as a Prime
Broker on behalf of the underlying Prime Brokerage clients. The shares are held
in an omnibus account. Since Merrill Lynch Professional Clearing Corporation has
the right of use over the shares although this entity does not have legal or
beneficial ownership, the shares are included as a Financial Instrument holding.

Full versions of all transparency notifications are available on Ablynx website,
under the section Investors.


About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
45 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple pharmaceutical
companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co.,
Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi
and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More
information can be found on www.ablynx.com.


For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  edwin.moses(at)ablynx.com

Lies Vanneste
Director Investor Relations
t:   +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e:  lies.vanneste(at)ablynx.com

Follow us on Twitter (at)AblynxABLX


Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx(at)consilium-comms.com


pdf version of the press release:
http://hugin.info/137912/R/2129959/813686.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ablynx via GlobeNewswire






More information:
http://www.ablynx.com http://www.ablynx.com



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: hugin
print pressrelease  send to a friend  

Date: 08/30/2017 - 07:00
Language: English
News-ID 1519166
Character count: 6253
Kontakt-Informationen:
Firma: Ablynx
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Ghent/Zwijnaarde
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 285

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 408
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 71


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.